Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal residual disease.
Medscape Medical News

source https://www.medscape.com/viewarticle/myeloma-adding-daratumumab-maintenance-therapy-improves-mrd-2024a1000hpn?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost